US EditionPublished • loading... • Updated
Canadian Blood Services reducing reliance on U.S. for life-changing plasma drugs
Canadian Blood Services and Grifols aim for 50% domestic immunoglobulin supply to reduce reliance on imports amid 10% annual demand growth, ensuring price protections.
- Canadian Blood Services aims to achieve 50% domestic self-reliance in producing immunoglobulins for Canadian patients to mitigate risks from potential U.S. supply disruptions.
- Canadian Blood Services has partnered with Grifols, a Barcelona-based company manufacturing plasma-derived medications, to open facilities in Montreal to produce immunoglobulins and albumin from Canadian-donated plasma.
- More plasma donors are needed as demand for immunoglobulin is projected to increase dramatically each year, and Canada currently relies heavily on U.S. supply.
Insights by Ground AI
32 Articles
32 Articles
The national agency wants to produce more immunoglobulins in the country and receive more plasma donations to do so, according to the CEO.
·Montreal, Canada
Read Full Article
Winnipeg Free Press+30 Reposted by 30 other sources
Canadian Blood Services reducing reliance on U.S. for life-changing plasma drugs
Breaking News, Sports, Manitoba, Canada
·Winnipeg, Canada
Read Full ArticleCoverage Details
Total News Sources32
Leaning Left19Leaning Right1Center4Last UpdatedBias Distribution79% Left
Bias Distribution
- 79% of the sources lean Left
79% Left
L 79%
C 17%
Factuality
To view factuality data please Upgrade to Premium
